ABSTRACT

Objectives: Primary: To explore anti-Müllerian Hormone (AMH) levels in community dwelling women following TBI. Secondary: To explore the relation of AMH to menstrual cycle, cognition, distress and symptoms of menopause.

Setting: Large adult TBI outpatient clinic in Toronto Canada.

Research design: Prospective study of 10 women with persistent symptoms who were one or more years post TBI.

Methods: Consenting participants provided a serum sample for AMH levels, and completed the Menopause Rating Scale (MRS), Symptom Checklist-90 r (SCL-90 r), Repeatable Battery for the Assessment of Neurological Status (RBANS) and a health questionnaire.

Main outcomes and results: This study found lower than expected levels of AMH in 50% of participants relative to age matched norms and 50% of participants experienced new onset of menstrual changes. Also notable were findings of lower-than-expected cognitive scores in women over 35 and reports of menopause-related symptoms across all ages groups.

Conclusions: As our understanding of the role of AMH grows, examining changes in this novel biomarker in the long-term post-TBI is warranted. Future research should be sufficiently powered to expand on and validate the study’s findings.

摘要

目的： 主要： 探讨 TBI 后社区居住妇女的抗苗勒管激素 (AMH) 水平。次要：探讨AMH与月经周期、认知、痛苦和更年期症状的关系。

地点：加拿大多伦多的大型成人 TBI 门诊。

研究设计：对 10 名在 TBI 后一年或以上有持续症状的女性进行的前瞻性研究。

方法：同意的参与者提供了 AMH 水平的血清样本，并完成了更年期评定量表 (MRS)、症状检查表-90 r (SCL-90 r)、用于评估神经状态的可重复电池 (RBANS) 和健康问卷。

主要结果和结果：本研究发现，相对于年龄匹配的标准，50% 的参与者的 AMH 水平低于预期，50% 的参与者经历了新的月经变化。同样值得注意的是 35 岁以上女性的认知评分低于预期，以及所有年龄段的更年期相关症状的报告。

结论：随着我们对 AMH 作用的理解不断加深，有必要在 TBI 后长期检查这种新型生物标志物的变化。未来的研究应该有足够的动力来扩展和验证研究结果。